Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 171-177

  Benito, J M ^a   Lopez M ^a   Lozano, S ^a   Ballesteros, C ^a   Gonzalez Lahoz J ^a   Soriano, V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV; Hydroxyurea; T cell activation; T cell proliferation

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; HYDROXYUREA; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE SURFACE MARKER;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYUREA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 34250188864     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03412.x     Document Type: Article

References (28)

1. Donehower R. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992 19 : 11 9.
2. Yarbro J. Mechanism of action of hydroxyurea. Semin Oncol 1992 19 : 1 10.
3. Lori F, Malykh A, Cara A et al. Hydroxyurea as inhibitor of HIV type 1 replication. Science 1994 266 : 801 5.
4. Gao W, Cara A, Gallo R, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit HIV type 1 replication. Proc Natl Acad Sci USA 1993 90 : 8925 8.
5. Lori F, Malykh A, Foli A et al. Combination of a drug targeting the cell with a drug targeting the virus controls HIV type 1 resistance. AIDS Res Hum Retroviruses 1997 13 : 1403 9.
6. Lori F. Hydroxyurea and HIV: 5 years later - from anti-viral to immune-modulating effects. AIDS 1999 13 : 1433 42.
7. De Boer R, Boucher A, Perelson A. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998 12 : 1567 70.
8. Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 1997 277 : 1437 8.
9. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999 15 : 619 24.
10. López M, Benito JM, Lozano S et al. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. AIDS 2004 18 : 1251 61.
11. Benito JM, López M, Ballesteros C et al. Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine. AIDS Res Hum Retroviruses 2006 22 : 734 43.
12. Wells A, Gudmundsdottir H, Turka L. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997 100 : 3173 83.
13. Lori F, Foli A, Groff A et al. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of anti-viral and cytostatic ('virostatic') mechanisms. AIDS 2005 19 : 1173 81.
14. Villani P, Maserati R, Regazzi M, Giacchino R, Lori F. Pharmacokinetics of hydroxyurea in patients infected with HIV type 1. J Clin Pharmacol 1996 36 : 117 21.
15. Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV cohort study. AIDS 1998 12 : F71 7.
16. Barreiro P, de Mendoza C, Camino N et al. Hydroxyurea plus didanosine as a maintenance therapy for HIV-infected patients on long-term successful highly active anti-retroviral therapy. HIV Clin Trials 2003 4 : 361 71.
17. Malhotra U, Bosch R, Wang R, Collier A, McElrath J. Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. AIDS Res Hum Retroviruses 2004 20 : 807 12.
18. Lova L, Groff A, Ravot E et al. Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS 2005 19 : 137 44.
19. Benito JM, López M, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V. CD38 expression on CD8+ lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving anti-retroviral therapy. AIDS Res Hum Retroviruses 2004 20 : 227 33.
20. Gougeon ML, Lecouer H, Dulioust A et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996 156 : 3509 20.
21. Benito JM, Martin J, López M et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2002 18 : 1379 88.
22. Bofill M, Mocroft A, Lipman M et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996 10 : 827 34.
23. Deeks S, Kitchen C, Liu L et al. Immune activation set-point during early HIV infection predicts subsequent CD4+ T cell changes independent of viral load. Blood 2004 104 : 942 7.
24. Wilson C, Ellenberg J, Douglas S, Moscicki AB, Holland CA. CD8+CD38+ T cells but not type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. Reach Project of the Adolescent Medicine HIV/AIDS Research Network. AIDS Res Hum Retroviruses 2004 20 : 263 9.
25. Vigano A, Saresella M, Villa ML, Ferrante P, Clerici M. CD38+CD8+ T cells as a marker of poor response to therapy in HIV-infected individuals. Chem Immunol 2000 75 : 207 12.
26. Hunt P, Martin J, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in HIV-infected patients with sustained viral suppression during anti-retroviral therapy. J Infect Dis 2003 187 : 1534 43.
27. Benito JM, López M, Lozano S et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2005 38 : 373 81.
28. Lori F, Rosenberg E, Lieberman J et al. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses 1999 15 : 1133 8.